tirzepatide surpass 5 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Tirzepatide Dosing Chart 2026: 2.5-15

We believe this is just the beginning of a broader shift in how GLP-1 treatments are priced and delivered across the country, and we'll keep working to make sure every Canadian has access to the care they deserve

Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders

The patients received 1 mg, 4 mg, 8 mg, and 12 mg of retatrutide once weekly for 48 weeks compared to placebo

In the intravital microscopy experiments, HFD-treated SAL-treated animals exhibited increased numbers of rolling and adhesive leukocytes on cerebral vessel walls

When each step is done carefully, the process is quick, safe, and effective

Endocrinology 141 , 111117 (2000)